Use of immunosuppressive agents for the treatment of schizophrenia
Patent 5912250 Issued on June 15, 1999. Estimated Expiration Date: January 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/9, Cyclopeptides514/105, Phosphorus is part of a ring514/263.2Additional hetero ring attached directly or indirectly to the purine ring system by nonionic bonding
A pharmaceutical composition for the treatment of schizophrenic disorders that comprises a pharmaceutically acceptable carrier and as active ingredient an immunosuppressive agent.
Other References
Shinitzky, Meir, et al., "Platelet Autoantibodies in Dementia and Schizophrenia, Possible Implication for Mental Disorders". Ann. N.Y. Academy Sciences, 1991; 621, pp. 205-217
DeLisi, Lynn E., et al., "Are there Antibodies Against Brain in Sera from Schizophrenia Patients? Review and Prospectus," Biol. Psychiatry, 1985, 20:94-119; pp. 110-115
Jankovic, B.D., "From Immunoneurology to Immunopsychiatry: Neuromodulating Activity of Anti-Brain Antibodies," International Review of Neurobiology, 1984, vol. 26, pp. 249-315
Knight, John G., "Is Schizophrenia an Autoimmune Disease?--A Review," Meth. and Find. Exptl. Clin. Pharmacol, 1984; 6(7), pp. 395-403
Teplizki, H. Amital, et al., "Autoantibodies to Brain and Polynucleotides in Patients with Schizophrenia: A Puzzle," Immunol. Res. 1992; 11, pp. 66-73
Kessler, A., et al., "Platelets from Schizophrenia Patients Bear Autoimmune Antibodies that Inhibit Dopamine Uptake," Psychobiology, 1993, 21 (4), pp. 299-306
Abramsky, O., et al., "Autoimmune Response to Dopamine-Receptor as a Possible Mechanism in the Pathogenesis of Parkinson's Disease and Schizophrenia," Perspectives in Biology and Medicine, 1978, pp. 104-114
Leporrier, M., et al., "Detection and Quantification of Platelet-bound Antibodies with Immunoperoxidase," British Journal of Haematology, 1979, 42, pp. 605-611
Ghadirian, A. M., "Some Recent Advances in the Study and Treatment of Schizophrenia in the Soviet Union," The Psychiatric Journal of the University of Ottawa, vol. II No. 3, pp. 112-116 (1980)
Levine, J., et al., "Treatment of Schizophrenia with an Immunosuppressant," The Lancet, vol. 344, Jul. 2, 1994, (8914) pp. 59-60
Price, John, et al., "A Case of Cerebral Systemic Lupus Erythematosus Treated with Methylprednisolone Pulse Therapy," Australian and New Zealand Journal of Psychiatry, (1985) 19, pp. 184-194
Valbonesi, M., et. al., "Plasma Exchange in Neurological Diseases, A Critical Approach," Vox Sang, 1983, 44, pp. 65-80
Kay, S. R., et al., "The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation," British Journal of Psychiatry (1989), 155 (suppl. 7), pp. 59-65
Kay, Stanley R., et al., "The Positive and Negative Syndrome Scale--Spanish Adaptation," The Journal of Nervous and Mental Disease, vol. 178, No. 8, pp. 510-517 (1982)
Budavari, S. (ED.), The Merck Index, 1989, Merck & Co., Inc., 11th Ed., Rahway, NJ, p. 431 and p. 1224
Ghadirian, Psychiatr. J. Univ. Ottawa, 2/3, pp. 112-116, 1977
Martindale The Extra Pharmacopoeia, 28th ed. pp. 190-191, 198
January 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
